Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2179 - Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-stage small-cell lung cancer (LD-SCLC): The final results of TORG 0604


08 Oct 2016


Poster Display


Yuki Misumi


Annals of Oncology (2016) 27 (6): 493-496. 10.1093/annonc/mdw389


Y. Misumi1, H. Okamoto1, K. Naoki2, Y. Hosomi3, T. Ogura4, N. Masuda5, K. Minato6, T. Yokoyama7, K. Kishi8, M. Nishikawa9, T. Kato10, N. Seki11, I. Goto12, K. Watanabe1

Author affiliations

  • 1 Department Of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, 240-8555 - Yokohama/JP
  • 2 Department Of Respiratory Medicine, Keio University School of Medicine, Tokyo/JP
  • 3 Department Of Thoracic Oncology And Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo/JP
  • 4 Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama/JP
  • 5 Respiratory Medicine, Kitasato University Hospital, Sagamihara/JP
  • 6 Department Of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota/JP
  • 7 Department Of Respiratory Medicine, Kyorin university Hospital, Mitaka/JP
  • 8 Dept. Of Respiratory Medicine, Toranomon Hospital, 105-8470 - Tokyo/JP
  • 9 Department Of Respiratory Medicine, Fujisawa Municipal Hospital, Fujisawa/JP
  • 10 Department Of Respiratory Medicine, Kanagawa Cancer Center, Yokohama/JP
  • 11 Department Of Medical Oncology, Teikyo University, Tokyo/JP
  • 12 Department Of Respiratory Medicine, Osaka Medical College, Takatsuki/JP


Abstract 2179


The role of irinotecan for elderly patients with LD-SCLC has been unclear, and the timing of TRT combined with chemotherapy has not been fully evaluated.


Patients aged > 70 years with untreated, measurable, LD-SCLC, performance status (PS) 0-2, and adequate organ function were eligible. Treatment consisted of induction with carboplatin on day 1 and irinotecan on days 1 and 8, every 21 days for 4 cycles, and sequential TRT (54Gy in 27 fractions). Carboplatin doses were based on AUC of 4 and 5 (levels 1 and 2, respectively), with a fixed irinotecan dose (50 mg/m2). Primary objectives of the phase II study were efficacy, adverse events, and feasibility.


Forty-one patients were enrolled (median age75 years [range 70-86 years); males 31; PS 0/1/2, n = 22/18/1]. The number of patients with carboplatin dose-limiting toxicities at levels-1 (n = 6) and -2 (n = 6) were 1(grade 3 hypertension) and 2 (grade 4 thrombocytopenia), respectively. The phase II trial was expanded to 29 additional patients receiving the level 1 carboplatin dose. The median number of chemotherapy cycles was 4 (range 1-4), and the median radiation dose was 54Gy (range 36-60).Toxicities were generally mild. There were 5 complete and 30 partial responses (response rate 90%).With a median follow-up of 80.4 months (n = 41), the median progression-free and overall survival times were 12.5 and 27.5 months, respectively.


Induction chemotherapy of carboplatin plus irinotecan and sequential TRT was well tolerated and effective for elderly patients with LD-SCLC. Additional confirmatory studies are warranted.

Clinical trial identification

Legal entity responsible for the study

Thoracic Oncology Reserch Group (TORG)


Nippon Kayaku, Taiho, Lilly, Sanofi, Chugai, Astra Zeneca, Daiichi Sankyo, Shionogi


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings